I can sit through a biotech presentation and come away convinced that the company has discovered the

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in p

New York, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a

Seth Fiegerman says Meta is moving aggressively into AI agents, with a new enterprise product that l

PRELIMINARY PROSPECTUSSubject to completion, dated September 25, 2026 751,879 Shares of Common Stock

THIO-104 advances toward key 2027 interim survival analysisCHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE)

THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE)

Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most r

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highligh

Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highligh

Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through ope

CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”,

PIMCO economist Tiffany Wilding said labor markets are no longer a major source of inflation pressur

Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vi

Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday

New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm

MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analy

Anna Edwards, Guy Johnson and Adam Linton break down today's key themes for analysts and investors o

90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy ob

90. 5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (G

Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recogniz

Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing wi

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-s

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap

Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an

THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in

MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026

MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst

US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vesse

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tues

Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical succ

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine se

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph